GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

CAR-T Digest - August 2020

Weekly Digest - May 2024

06 May 2024: GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

Guangzhou-Israel Biotechnology Fund (GIBF) invested $10 million in Nectin Therapeutics Ltd.
The funds will support ongoing clinical development of Nectin’s lead program targeting PVR (CD155) and IND-enabling activities for multiple antibody-drug conjugates (ADCs)
NTX1088 is Nectin’s First-in-Class lead candidate antibody and targets PVR (CD155), a protein on cancer cells linked to immune checkpoint inhibitor resistance
High PVR levels correlate with poor prognosis and resistance to PD1 and PDL1 inhibitors, highlighting its potential as a target for monotherapy or combination therapies

For full story click here